|Bid||0.00 x 3200|
|Ask||0.00 x 1200|
|Day's range||18.73 - 20.70|
|52-week range||1.92 - 33.79|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.33|
There are no signs the coronavirus pandemic is slowing down in the U.S., with more than 1,100 Americans dying every day from COVID-19 in recent days. Beyond the staggering fatalities, one estimate by the Australian National University puts the virus' potential global economic damage at over $21 trillion. The need for a coronavirus vaccine has thus become paramount to saving lives and mitigating economic catastrophes.
Microsoft Co-Founder Bill Gates joins 'Influencers with Andy Serwer' to discuss the U.S. federal government's pandemic response and how it can improve.
What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 4.2% higher as of 11:15 a.m. EDT on Thursday after rising as much as 17.7% earlier in the day. The gain came on Inovio's announcement Thursday morning of results from preclinical testing of COVID-19 vaccine candidate INO-4800.